JP2007502808A5 - - Google Patents

Download PDF

Info

Publication number
JP2007502808A5
JP2007502808A5 JP2006523697A JP2006523697A JP2007502808A5 JP 2007502808 A5 JP2007502808 A5 JP 2007502808A5 JP 2006523697 A JP2006523697 A JP 2006523697A JP 2006523697 A JP2006523697 A JP 2006523697A JP 2007502808 A5 JP2007502808 A5 JP 2007502808A5
Authority
JP
Japan
Prior art keywords
chlorophenyl
phenyl
aza
hydroxy
bicyclo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006523697A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007502808A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2004/002596 external-priority patent/WO2005018645A1/en
Publication of JP2007502808A publication Critical patent/JP2007502808A/ja
Publication of JP2007502808A5 publication Critical patent/JP2007502808A5/ja
Pending legal-status Critical Current

Links

JP2006523697A 2003-08-21 2004-08-09 哺乳類における依存症の予防と治療のための薬剤組成物 Pending JP2007502808A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49680303P 2003-08-21 2003-08-21
PCT/IB2004/002596 WO2005018645A1 (en) 2003-08-21 2004-08-09 A pharmaceutical composition for the prevention and treatment of addiction in a mammal

Publications (2)

Publication Number Publication Date
JP2007502808A JP2007502808A (ja) 2007-02-15
JP2007502808A5 true JP2007502808A5 (enExample) 2007-08-16

Family

ID=34216038

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006523697A Pending JP2007502808A (ja) 2003-08-21 2004-08-09 哺乳類における依存症の予防と治療のための薬剤組成物

Country Status (7)

Country Link
US (1) US20050043327A1 (enExample)
EP (1) EP1658082A1 (enExample)
JP (1) JP2007502808A (enExample)
BR (1) BRPI0413693A (enExample)
CA (1) CA2536280A1 (enExample)
MX (1) MXPA06002035A (enExample)
WO (1) WO2005018645A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4155522B2 (ja) * 2001-10-22 2008-09-24 ファイザー・プロダクツ・インク オピオイド受容体アンタゴニストとしての3−アザビシクロ(3.1.0)ヘキサン誘導体
JP5189242B2 (ja) * 2002-09-23 2013-04-24 アルケルメス ファーマ アイルランド リミテッド 乱用抵抗性の医薬組成物
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
RS20050532A (sr) 2003-01-14 2007-12-31 Arena Pharmaceuticals Inc., Derivati 1,2,3-trisupstituisanog arila i heteroarila kao modulatori metabolizma za profilaksu i tretman poremećaja povezanih sa njim, kao što su dijebetes i hiperglikemija
KR20060056944A (ko) * 2003-07-14 2006-05-25 아레나 파마슈티칼스, 인크. 대사 조절제로서 융합된 아릴 및 헤테로아릴 유도체 및이에 관련된 장애의 예방 또는 치료
US8188097B2 (en) 2005-10-21 2012-05-29 Mitsubishi Tanabe Pharma Corporation Pyrazolo[1,5-A]pyrimidine compounds
AR061793A1 (es) 2006-07-05 2008-09-24 Mitsubishi Tanabe Pharma Corp Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica
WO2008039023A1 (en) * 2006-09-29 2008-04-03 Green Cross Corporation Heteroaryl-pyrazole derivatives as cannabinoid cb1 receptor antagonists
WO2008044111A1 (en) * 2006-10-13 2008-04-17 Pfizer Products Inc. Pharmaceutical formulation tablet
JP3145620U (ja) 2008-07-30 2008-10-16 公二 平井 擬似嗜好物品
WO2010019762A1 (en) * 2008-08-13 2010-02-18 Jenrin Discovery Purine compounds as cannabinoid receptor blockers
UA104010C2 (en) * 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
CN103221410B (zh) 2010-09-22 2017-09-15 艾尼纳制药公司 Gpr119受体调节剂和对与其相关的障碍的治疗
KR20140003438A (ko) 2010-11-15 2014-01-09 카톨리에케 유니버시테이트 루벤 항바이러스성 축합 헤테로사이클릭 화합물
DK3072884T3 (da) 2013-11-20 2020-03-09 Sanwa Kagaku Kenkyusho Co 3-azabicyclo[3.1.0]hexanderivat og anvendelse deraf til medicinske formål
CA3002540C (en) 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
MX388953B (es) 2015-05-20 2025-03-20 Ube Industries Cristal de sal de derivado de 3-azabiciclo[3.1.0]hexano novedoso y usos medicionales del mismo.
EP3558996A4 (en) * 2016-12-21 2020-08-05 Research Triangle Institute, International DIARYLPURINE DERIVATIVES WITH ENHANCED BIOAVAILABILITY
KR20190120212A (ko) * 2017-03-02 2019-10-23 가부시키가이샤산와카가쿠켄큐쇼 알코올 사용 장해의 치료약
US10604489B2 (en) * 2018-02-05 2020-03-31 Alkermes, Inc. Compounds for the treatment of pain
US11795146B2 (en) 2021-10-11 2023-10-24 Anebulo Pharmaceuticals, Inc. Crystalline forms of a cannabinoid receptor type 1 (CB1) modulator and methods of use and preparation thereof
WO2023064228A1 (en) * 2021-10-11 2023-04-20 Anebulo Pharmaceuticals, Inc. Method of treating addiction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4155522B2 (ja) * 2001-10-22 2008-09-24 ファイザー・プロダクツ・インク オピオイド受容体アンタゴニストとしての3−アザビシクロ(3.1.0)ヘキサン誘導体
BR0314872A (pt) * 2002-10-18 2005-08-02 Pfizer Prod Inc Ligandos do receptor canabinóide e usos dos mesmos
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) * 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) * 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof

Similar Documents

Publication Publication Date Title
US20060111348A1 (en) Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
WO2004089416A2 (en) Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent
US20090264412A1 (en) Combination Therapy Using An 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor And A Glucocorticoid Receptor Agonist To Minimize The Side Effects Associated With Glucocorticoid Receptor Agonist Therapy
JP2006522750A5 (enExample)
US20050043327A1 (en) Pharmaceutical composition for the prevention and treatment of addiction in a mammal
JP6185574B2 (ja) 耳鳴りを治療するためのh4受容体阻害剤
EP1615667A2 (en) Combinations of an 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist
JP2012532152A5 (enExample)
EP2010177A2 (en) Combination histamine h1r and h4r antagonist therapy for treating pruritus
JP2015512888A5 (enExample)
AU2003212268A1 (en) Pharmaceutical composition of a PDE4 or PDE3/4 inhibitor and a histamine receptor antagonist
US10195195B2 (en) Selective histamine H4 receptor antagonists for the treatment of vestibular disorders
RU2005131497A (ru) Фармацевтическая композиция для предотвращения и лечения аддикции к никотину у млекопитающего
EP1626738A2 (en) A pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
EP1862181A2 (en) Combination therapy using an 11B-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
EP1854487A2 (en) Combinations of an 11-beta-hydroxysteroid dehaydrogenase type 1 inhibitor and a glucocorticoid receptor agonist
EP1615666A2 (en) Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent